secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-150894
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022
-----------------------------------------------------------

- Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.
- Plans to submit NDA for avasopasem for severe oral mucositis by end of 2022 after FDA discussions.
- Phase 3 ROMAN data accepted for oral presentation at 2022 ASCO; positive Phase 2a AESOP data reported.
- R&D expenses $8.1M (down from $12.4M); G&A expenses $5.0M (flat).
- Enrollment ongoing in Phase 2b GRECO-2 trial of rucosopasem for pancreatic cancer and Phase 1/2 GRECO-1 for NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/0001193125-22-150894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312522150894/d277547d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer